Your session is about to expire
← Back to Search
TGF-beta Resistant Cytotoxic T-lymphocytes for Nasopharyngeal Cancer
Study Summary
This trial is a Phase I study which will test the safety of the DNR.NPC-specific T cells. The study will also help us to understand how well the cells work in patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not pregnant, breastfeeding, or have a severe infection.I have nasopharyngeal carcinoma that has returned or didn't respond to treatment, and it's EBV positive. I've signed the informed consent.
Frequently Asked Questions
What are the results of past research conducted on DNR.NPC-specific T cells?
"Currently, 889 clinical trials studying DNR.NPC-specific T cells are active with 161 of those studies in Phase 3. 28446 medical centres around the world have registered for this investigation, many located in Pennsylvania's Philadelphia county."
How many participants have signed up for this medical experiment?
"Unfortunately, this clinical trial is not currently recruiting. Initially posted on February 1st 2015 and last edited on the same date in 2022, patient recruitment for this study has been suspended at present. On the other hand, there are presently 2512 studies actively looking to enrol ebv-positive nasopharyngeal carcinoma patients and 889 trials searching for DNR.NPC-specific T cell candidates."
To what purpose is DNR.NPC-specific T cell infusion generally utilized?
"DNAR.NPC-specific T cells is commonly used to manage the symptoms of multiple sclerosis, but are likewise effective at treating various other illnesses including myelocytic leukemia, mixed cell type lymphoma, acute retinoblastoma and more."
Is there currently any opportunity to join this trial?
"This clinical trial is no longer enrolling participants, as the last update was made on February 1st 2022. However, there are an abundance of other studies available to join with over 3401 trials actively recruiting right now."
Are there any potential risks associated with the utilization of DNR.NPC-specific T cells?
"Our team at Power has assigned DNR.NPC-specific T cells a score of 1 due to the limited data present for its efficacy and safety that is typical of Phase 1 trials."
Share this study with friends
Copy Link
Messenger